(Bloomberg) — Novartis AG agreed to buy Medicines Co. for about $6.8 billion, snapping up a promising cholesterol drug and adding to a string of recent acquisitions for Chief Executive Officer Vas Narasimhan.Medicines Co. shareholders will get $85 a share, Basel, Switzerland-based Novartis said in a statement on Sunday. That’s a 45% premium to the closing price on Nov. 18, before Bloomberg reported the two companies were in talks. The transaction value reaches $9.7 billion on a fully diluted basis that includes outstanding stock options and convertible debt, Novartis said.The deal brings an experimental cholesterol treatment, inclisiran, into a stable …read more
Source:: Yahoo Finance
